Targeted therapy for EGFR-mutant lung cancer with brain spread
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have stage 4 non-small cell lung cancer.
- Your tumor has an EGFR mutation (a specific change in the cancer cells) called exon 19 deletion or L858R.
- You have brain metastases (cancer that has spread to your brain) seen on CT or MRI.
- You have not had any prior treatment for advanced lung cancer, except maybe local therapy like radiation that didn't affect the tumor you're measuring.
- Your blood counts and organ function (like kidney and liver) are within certain limits.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests a combination of two targeted therapy drugs (furmonertinib and anlotinib) for people with advanced lung adenocarcinoma that has spread to the brain and has an EGFR mutation. The goal is to see if this combination can shrink or control the brain tumors.
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
This trial compares two doses of the targeted drug furmonertinib (80 mg vs 160 mg) combined with chemotherapy for people with EGFR-mutated lung cancer that has spread to the brain. It aims to find out which dose works better and is safer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.